골다공증 치료의 최신 지견: 누구를, 무엇으로, 얼마 동안 치료할 것인가?

키워드

참고문헌 (78)

1. Choi YJ, "The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program : the Korea National Health and Nutrition Examination Survey 2008-2009", J Bone Miner Res, 27, pp.1879~1886 (2012)
2. Shin CS, "Prevalence and risk factors of osteoporosis in Korea: a community-based cohort study with lumbar spine and hip bone mineral density", Bone, 47, pp.378~387 (2010)
3. 이영균, "Epidemiology of Osteoporosis and Osteoporotic Fractures in South Korea", Endocrinology and Metabolism, 28(2), pp.90~93 (2013), 대한내분비학회
4. "Report" (2013)[URL]
5. "Clinician's guide to prevention and treatment of osteoporosis" (2013)[URL]
6. Kanis JA, "FRAX and its applications to clinical practice", Bone, 44, pp.734~743 (2009)
7. Dunford JE, "Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates", J Pharmacol Exp Ther, 296, pp.235~242 (2001)
8. Van Beek E, "Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase", farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo, 1999, pp.255, 491~494
9. Fisher JE, "Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro", Proc Natl Acad Sci U S A, 96, pp.133~138 (1999)
10. Luckman SP, "Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras", J Bone Miner Res, 13, pp.581~589 (1998)
11. Welton JL, "Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate : insights from a phase IV safety trial", J Bone Miner Res, 28, pp.464~471 (2013)
12. Khosla S, "Bisphosphonate-associated osteonecrosis of the jaw : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
13. Rizzoli R, "Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis", Ther Adv Musculoskelet Dis, 2, pp.3~16 (2010)
14. Assael LA., "Oral bisphosphonates as a cause of bisphosphonate- related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies", J Oral Maxillofac Surg, 67(5), pp.35~43 (2009)
15. Fleisher KE, "Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy", J Oral Maxillofac Surg, 71, pp.513~519 (2013)
16. Marx RE, "Bisphosphonate- induced exposed bone (osteonecrosis", osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment, 2005, pp.63, 1567~1575
17. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 25, pp.2267~2294 (2010)
18. Abrahamsen B, "Beyond a reasonable doubt? b isphosphonates and atypical femur fractures", Bone, 50, pp.1196~1200 (2012)
19. Davey RA, "Calcitonin: physiology or fantasy?", J Bone Miner Res, 28, pp.973~979 (2013)
20. Shlossman M, "Calcitonin effects on isolated bone cells", Calcif Tissue Int, 34, pp.190~196 (1982)
21. "Questions and answers on the review of calcitonin containing medicines: outcome of a procedure under article 31 of directive 2001/83/EC" (2012)[URL]
22. "Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer: Collaborative Group on Hormonal Factors in Breast Cancer", Lancet, 350, pp.1047~1059 (1997)
23. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
24. Delmas PD, "Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women", N Engl J Med, 337, pp.1641~1647 (1997)
25. Recker RR, "Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass", Bone, 40, pp.843~851 (2007)
26. Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", N Engl J Med, 355, pp.125~137 (2006)
27. Lee WL, "Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women", Maturitas, 60, pp.92~107 (2008)
28. Ming LG, "Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling", J Cell Physiol, 228, pp.513~521 (2013)
29. Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)
30. Seeman E, "Microarchitectural deterioration of cortical and trabecular bone : differing effects of denosumab and alendronate", J Bone Miner Res, 25, pp.1886~1894 (2010)
31. Malan J, "The relationship of denosumab pharmacology and osteonecrosis of the jaws", Oral Surg Oral Med Oral Pathol Oral Radiol, 114, pp.671~676 (2012)
32. Watson PH, "Parathyroid hormone : regulation of synthesis and secretion", Clin Invest Med, 16, pp.58~77 (1993)
33. Reeve J, "Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis : a multicentre trial", Br Med J, 280, pp.1340~1344 (1980)
34. Finkelstein JS, "Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis", J Clin Endocrinol Metab, 95, pp.1838~1845 (2010)
35. Saag KG, "Teriparatide or alendronate in glucocorticoid-induced osteoporosis", N Engl J Med, 357, pp.2028~2039 (2007)
36. Yamamoto T, "Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg", day administered subcutaneously in Japanese patients with osteoporosis, 2013, pp.31, 199~205
37. Jilka RL, "Molecular and cellular mechanisms of the anabolic effect of intermittent PTH", Bone, 40, pp.1434~1446 (2007)
38. Black DM, "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis", N Engl J Med, 349, pp.1207~1215 (2003)
39. Miller PD, "Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate", J Clin Endocrinol Metab, 93, pp.3785~3793 (2008)
40. Tsai JN, "in women with postmenopausal osteoporosis : the DATA study randomised trial", Lancet, 382, pp.50~56 (2013)
41. Andrews EB, "The US postmarketing surveillance study of adult osteosarcoma and teriparatide : study design and findings from the first 7 years", J Bone Miner Res, 27, pp.2429~2437 (2012)
42. ), "J Toxicol Sci", 2012, 617~629
43. Shiraki M, "Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women", Osteoporos Int, 24, pp.219~226 (2013)
44. Devogelaer JP, "Biologicals in osteoporosis : teriparatide and parathyroid hormone in women and men", Curr Osteoporos Rep, 8, pp.154~161 (2010)
45. Farra R, "First-in-human testing of a wirelessly controlled drug delivery microchip", Sci Transl Med, 4, pp.122~ (2012)
46. Inaoka T, "Molecular cloning of human cDNA for cathepsin K : novel cysteine proteinase predominantly expressed in bone", Biochem Biophys Res Commun, 206, pp.89~96 (1995)
47. Li YP, "Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas", J Bone Miner Res, 10, pp.1197~1202 (1995)
48. Gelb BD, "Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency", Science, 273, pp.1236~1238 (1996)
49. Saftig P, "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice", Proc Natl Acad Sci U S A, 95, pp.13453~13458 (1998)
50. Gauthier JY, "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K", Bioorg Med Chem Lett, 18, pp.923~928 (2008)
51. Pérez-Castrillón JL, "Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women", J Osteoporos, 2010, pp.401581~ (2010)
52. Ng KW, "Potential role of odanacatib in the treatment of osteoporosis", Clin Interv Aging, 7, pp.235~247 (2012)
53. Balemans W, "Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein(SOST)", Hum Mol Genet, 10, pp.537~543 (2001)
54. Lin C, "Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt", beta-catenin signaling, 2009, pp.24, 1651~1661
55. Spatz JM, "Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading", J Bone Miner Res, 28, pp.865~874 (2013)
56. Costa AG, "Sclerostin : therapeutic horizons based upon its actions", Curr Osteoporos Rep, 10, pp.64~72 (2012)
57. Padhi D, "Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody", J Bone Miner Res, 26, pp.19~26 (2011)
58. Steinert AF, "Concise review : the clinical application of mesenchymal stem cells for musculoskeletal regeneration : current status and perspectives", Stem Cells Transl Med, 1, pp.237~247 (2012)
59. Guan M, "Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass", Nat Med, 18, pp.456~462 (2012)
60. Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial : Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators", JAMA, 282, pp.637~645 (1999)
61. Delmas PD, "Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four-year results from a randomized clinical trial", J Clin Endocrinol Metab, 87, pp.3609~3617 (2002)
62. Cummings SR, "Lasofoxifene in postmenopausal women with osteoporosis", N Engl J Med, 362, pp.686~696 (2010)
63. De Villiers TJ, "placebo-controlled phase 3 trial", Osteoporos Int, 22, pp.567~576 (2011)
64. Silverman SL, "Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study", Osteoporos Int, 23, pp.351~363 (2012)
65. Siris ES, "Skeletal effects of raloxifene after 8 years : results from the continuing outcomes relevant to Evista(CORE)Study", J Bone Miner Res, 20, pp.1514~1524 (2005)
66. Lippman ME, "Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk", Clin Cancer Res, 12, pp.5242~5247 (2006)
67. Martino S, "Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene", J Natl Cancer Inst, 96, pp.1751~1761 (2004)
68. Whitaker M, "Bisphosphonates for osteoporosis: where do we go from here?", N Engl J Med, 366, pp.2048~2051 (2012)
69. Sorensen OH, "Long-term efficacy of risedronate : a 5-year placebo-controlled clinical experience", Bone, 32, pp.120~126 (2003)
70. Black DM, "Effects of continuing or stopping alendronate after 5 years of treatment : the Fracture Intervention Trial Long-term Extension(FLEX) : a randomized trial", JAMA, 296, pp.2927~2938 (2006)
71. Ensrud KE, "Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD : results from the Fracture Intervention Trial long-term extension", J Bone Miner Res, 19, pp.1259~1269 (2004)
72. Black DM, "Continuing bisphosphonate treatment for osteoporosis: for whom and for how long?", N Engl J Med, 366, pp.2051~2053 (2012)
73. Bone HG, "Ten years' experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004)
74. Mellström DD, "Seven years of treatment with risedronate in women with postmenopausal osteoporosis", Calcif Tissue Int, 75, pp.462~468 (2004)
75. Devogelaer JP, "Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis", Osteoporos Int, 18, pp.1211~1218 (2007)
76. Papapoulos S, "Five years of denosumab exposure in women with postmenopausal osteoporosis : results from the first two years of the FREEDOM extension", J Bone Miner Res, 27, pp.694~701 (2012)
77. Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial", Bone, 43, pp.222~229 (2008)
78. Miller PD, "Effect of denosumab on bone mineral density and biochemical markers of bone turnover : six-year results of a phase 2 clinical trial", J Clin Endocrinol Metab, 96, pp.394~402 (2011)

관련 논문AI추천